Cargando…
Radiation-induced malignancies following radiotherapy for breast cancer
With advances in diagnosis and treatment, breast cancer is becoming an increasingly survivable disease resulting in a large population of long-term survivors. Factors affecting the quality of life of such patients include the consequences of breast cancer treatment, which may have involved radiother...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409877/ https://www.ncbi.nlm.nih.gov/pubmed/15292931 http://dx.doi.org/10.1038/sj.bjc.6602084 |
_version_ | 1782155887873359872 |
---|---|
author | Roychoudhuri, R Evans, H Robinson, D Møller, H |
author_facet | Roychoudhuri, R Evans, H Robinson, D Møller, H |
author_sort | Roychoudhuri, R |
collection | PubMed |
description | With advances in diagnosis and treatment, breast cancer is becoming an increasingly survivable disease resulting in a large population of long-term survivors. Factors affecting the quality of life of such patients include the consequences of breast cancer treatment, which may have involved radiotherapy. In this study, we compare the incidence of second primary cancers in women who received breast radiotherapy with that in those who did not (non-radiotherapy). All women studied received surgery for their first breast cancer. Second cancers of the lung, colon, oesophagus and thyroid gland, malignant melanomas, myeloid leukaemias and second primary breast cancers were studied. Comparing radiotherapy and non-radiotherapy cohorts, elevated relative risks (RR) were observed for lung cancer at 10–14 years and 15 or more (15+) years after initial breast cancer diagnosis (RR 1.62, 95% confidence interval [CI] 1.05–2.54 and RR 1.49, 95% CI 1.05–2.14, respectively), and for myeloid leukaemia at 1–5 years (RR 2.99, 95% CI 1.13–9.33), for second breast cancer at 5–10 years (RR 1.34, 95% CI 1.10–1.63) and 15+ years (RR 1.26, 95% CI 1.00–1.59) and oesophageal cancer at 15+ years (RR 2.19, 95% CI 1.10–4.62). |
format | Text |
id | pubmed-2409877 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-24098772009-09-10 Radiation-induced malignancies following radiotherapy for breast cancer Roychoudhuri, R Evans, H Robinson, D Møller, H Br J Cancer Clinical With advances in diagnosis and treatment, breast cancer is becoming an increasingly survivable disease resulting in a large population of long-term survivors. Factors affecting the quality of life of such patients include the consequences of breast cancer treatment, which may have involved radiotherapy. In this study, we compare the incidence of second primary cancers in women who received breast radiotherapy with that in those who did not (non-radiotherapy). All women studied received surgery for their first breast cancer. Second cancers of the lung, colon, oesophagus and thyroid gland, malignant melanomas, myeloid leukaemias and second primary breast cancers were studied. Comparing radiotherapy and non-radiotherapy cohorts, elevated relative risks (RR) were observed for lung cancer at 10–14 years and 15 or more (15+) years after initial breast cancer diagnosis (RR 1.62, 95% confidence interval [CI] 1.05–2.54 and RR 1.49, 95% CI 1.05–2.14, respectively), and for myeloid leukaemia at 1–5 years (RR 2.99, 95% CI 1.13–9.33), for second breast cancer at 5–10 years (RR 1.34, 95% CI 1.10–1.63) and 15+ years (RR 1.26, 95% CI 1.00–1.59) and oesophageal cancer at 15+ years (RR 2.19, 95% CI 1.10–4.62). Nature Publishing Group 2004-08-31 2004-08-03 /pmc/articles/PMC2409877/ /pubmed/15292931 http://dx.doi.org/10.1038/sj.bjc.6602084 Text en Copyright © 2004 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Roychoudhuri, R Evans, H Robinson, D Møller, H Radiation-induced malignancies following radiotherapy for breast cancer |
title | Radiation-induced malignancies following radiotherapy for breast cancer |
title_full | Radiation-induced malignancies following radiotherapy for breast cancer |
title_fullStr | Radiation-induced malignancies following radiotherapy for breast cancer |
title_full_unstemmed | Radiation-induced malignancies following radiotherapy for breast cancer |
title_short | Radiation-induced malignancies following radiotherapy for breast cancer |
title_sort | radiation-induced malignancies following radiotherapy for breast cancer |
topic | Clinical |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409877/ https://www.ncbi.nlm.nih.gov/pubmed/15292931 http://dx.doi.org/10.1038/sj.bjc.6602084 |
work_keys_str_mv | AT roychoudhurir radiationinducedmalignanciesfollowingradiotherapyforbreastcancer AT evansh radiationinducedmalignanciesfollowingradiotherapyforbreastcancer AT robinsond radiationinducedmalignanciesfollowingradiotherapyforbreastcancer AT møllerh radiationinducedmalignanciesfollowingradiotherapyforbreastcancer |